Page 104 - GTM-2-1
P. 104

Global Translational Medicine                                       GalNAc AGT ASO reduce atherosclerosis



            adventitial tissues were removed, and the intimal surface   2.8. Statistical analysis
            was exposed by a longitudinal cut and pinned on a black   There were two types of data in this study: non-repeated
            rubber surface. Images of en face aortas were taken using   measures after termination, and repeated measures
            a digital camera (Nikon Digital Sight DS-Ri1), with a ruler   during the study. Prism v9 (GraphPad Software Inc.,
            for calibration.                                   La Jolla) was used for non-repeated measures, while R
              An en face method was used to measure atherosclerotic   version  4.2.1 was used for repeated measures. Before
            lesions on the intimal surface of the aorta in accord with   analyzing non-repeated measures, normality and
            the American Heart Association (AHA) statement and   homogeneous variance assumptions were tested with
            as detailed in our standard protocol [16,17] . Atherosclerotic   Shapiro–Wilk and Brown-Forsythe tests, respectively.
            lesions were traced manually from the ascending aorta to   Since these assumptions were satisfied, all non-repeated
            the proximal part of the descending thoracic aorta (1 mm   data were analyzed using one-way analysis of variance
            distal from the orifice of the left subclavian artery) using   (ANOVA) to compare means among three or more
            Nikon NIS-Elements software (NIS-Elements AR 5.11.00.)   groups, followed by the Sidak post hoc test. For repeated
            under a dissecting microscope.                     measures, mixed-effect models with inverse-variance
                                                               weights were used with random intercept and slope for
            2.5. Histology                                     time. A piecewise model was fitted to estimate separate
            At termination, a piece of each liver sample was fixed   slopes for distinct time points (-2 to 0 and 0 to 11 weeks)
            in  paraformaldehyde (4%  wt/vol)  overnight and  then   in plasma AGT concentrations. The mixed-effect models
            embedded in paraffin. Five-micron sections were used   were run using the lme function in the nlme R package.
            for hematoxylin and eosin (H&E) staining. In addition,   Data  of non-repeated  measures  were represented  as
            a piece of liver (fresh frozen) was embedded in optimal   individual data points and mean ± standard error of the
            cutting temperature compound (OCT; Cat # 14-373-65,   mean (SEM). P < 0.05 or Bonferroni-corrected P < 0.05
            Fisher Scientific), sectioned using a cryostat (Leica CM   was considered statistically significant.
            1850, Leica) at 10 µm/section, and stained with Oil Red O   3. Results
            to visualize neutral lipid accumulation.
                                                               3.1. N-acetylgalactosamine-conjugated antisense
            2.6. Quantification of liver steatosis             oligonucleotides targeting angiotensinogen
            Liver weights were recorded at termination. A  small   reduced blood pressure, atherosclerosis, and
            piece of liver was snap-frozen in liquid nitrogen. Liver   Western diet-induced liver steatosis
            lipids were extracted, solubilized with Triton X-100, and   In the vehicle group, plasma AGT remained unaltered
            quantified using enzymatic assays kits for total cholesterol   (Figure 1B) in mice fed either normal laboratory diet
            (Cat # 23-66-201, Pointe Scientific Cholesterol reagent),   (from week -2 to week 0) or Western diet (from week
            and triglycerides (Regents 1 and 2: Cat # 994-02891 and   0 through week 12). GalNAc AGT ASO significantly
            Cat # 990-0299, Fujifilm Healthcare) .             reduced  plasma  AGT concentrations  in mice when
                                         [18]
                                                               they were fed normal laboratory diet; Western diet
            2.7. RNA isolation and quantitative polymerase     did not alter this outcome. All three doses of GalNAc
            chain reaction (PCR)                               AGT ASO yielded the same degree of AGT lowering,

            Total RNA was extracted from liver and kidney samples using   maximally  reducing plasma AGT by ~90%. GalNAc
            a commercial kit (Cat # AS1280, Promega) and the automated   AGT ASO reduced systolic BP in a dose-dependent
            Maxwell   RSC 48 Instrument (Promega). To quantify   manner  versus  vehicle  (Figure  1C),  with  the  effect
                  ®
            mRNA abundance, total RNA was reversely transcribed with   at 5  mg/kg being significantly larger than that at
            iScript cDNA Synthesis kit (Cat # 170-8891, Bio-Rad), and   1  mg/kg (P  < 0.001). Similarly, a dose-dependent
            quantitative PCR (qPCR) was performed using the TaqMan   reduction in atherosclerotic lesion size was observed
            Fast Advances Master Mixes kit (Cat # A44359, Thermo Fisher   (Figure 1D and E).
            Scientific) on a Bio-Rad CFX96 cycler. TaqMan assay primers:   LDL receptor mice fed a Western diet developed liver
                                                                          -/- 
            Agt (ID: Mm00599662_m1),  Ren1 (ID: Mm02342889_g1),   steatosis with increased liver weight and liver cholesterol
            Gapdh (ID: Mm99999915_g1), Actb (ID: Mm01205647_g1),   and triglyceride content [8,19-22] . The results obtained in this
            and Ppia (ID: Mm02342429_g1). Data were analyzed using   study (Figure  2A–C) confirmed this outcome. GalNAc
            the ∆∆Ct method and normalized with the geometric mean   AGT ASO administration reduced liver weight and liver
            of the three reference genes: Gapdh, Actb, and Ppia.  total cholesterol and triglyceride content (Figures 2A–C)



            Volume 2 Issue 1 (2023)                         4                         https://doi.org/10.36922/gtm.288
   99   100   101   102   103   104   105   106   107   108   109